Introduction {#Sec1}
============

Obesity is increasingly prevalent after solid organ transplantation, and may negatively impact the transplant population on multiple levels \[[@CR1]--[@CR6]\]. Obesity in transplantation patients may also negatively impact perioperative and long-term outcomes after metabolic and bariatric surgery (MBS) \[[@CR7]--[@CR11]\]. In the systematic review by Sood et al., obesity was associated with a higher odds ratio for biopsy-proven acute rejection, mortality, allograft loss, and the development of diabetes \[[@CR8]\]. Patients with a history of solid organ transplantation are routinely considered to be high-risk patients. This risk stratification is compounded by the presence and disease burden of obesity. Given its safety profile and health impact, there is increasing interest in the role of MBS in obese patients with prior organ transplantation. Therefore, the aim of this study is to compare outcomes of the largest North American patient cohort, with and without a history of solid organ transplantation, undergoing metabolic and bariatric surgery.

Material and Methods {#Sec2}
====================

Data Source {#Sec3}
-----------

We performed a retrospective analysis of data from the 2017 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Participant Use Files (PUF) database, and compared outcomes between those with and without a history of previous solid organ transplantation. The MBSAQIP is responsible for the accreditation of bariatric surgical facilities. Requirements for certification include reporting bariatric surgical outcomes to the MBSAQIP Participant Use Data File (PUF), a Health Insurance Portability and Accountability Act (HIPAA)-compliant data file registry containing prospectively entered, risk-adjusted, clinically rich data using standardized definitions for preoperative, intraoperative, and post-operative variables that are specific to metabolic and bariatric surgical care. Data points are abstracted at participating institutions by certified reviewers who are audited for accuracy of performance. For the first time, the 2017 file included data on previous solid organ transplantation, including a history of heart, lung, liver, renal, pancreas, and bowel transplantation. The database does not give the ability to discern which type of transplant has been performed. This is a de-identified, nationally available, clinical database; therefore, neither institutional review board (IRB) approval nor patient consent was required for our study.

Case Selection and Inclusion Criteria {#Sec4}
-------------------------------------

A patient selection diagram is shown in Fig. [1](#Fig1){ref-type="fig"}. Participants included patients who had a primary gastric bypass (RYGB) or sleeve gastrectomy (SG) in 2017, designated by Current Procedural Terminology (CPT) codes 43644, 43645, and 43775. We excluded patients less than 18 years or greater than 80 years old, body mass index (BMI) \< 35, any bariatric procedure other than a RYGB or SG, bariatric procedures designated as emergency, open cases, revision/conversion cases, and those with incomplete clinical data. Selected cases were further stratified by a history of solid organ transplantation (TXP). There were 614 TXP patients in the 2017 MBSAQIP database prior to exclusions. 336 were included in our analysis. A total of 278 TXP patients were excluded from analysis for the following reasons: age \< 18 or \> 80 years old (*n* = 1), BMI \< 35 (*n* = 136), having a prior bariatric surgery (*n* = 40), emergency cases (*n* = 22), open surgical approach (*n* = 9), and incomplete data (*n* = 70).Fig. 1Patient selection strategy

Data Collection and Statistical Analysis {#Sec5}
----------------------------------------

Descriptive statistics were collected and compared between groups, including demographics, health summary status, preoperative comorbidities, and operative characteristics. Primary outcome measures included 30-day mortality and morbidity. Secondary outcome measures included other 30-day adverse outcomes (reoperation, readmission, and reintervention), post-operative complication, composite complications, operative duration, conversion, and hospital length of stay. Unmatched cohorts were compared by univariate analysis, using Pearson chi-square test for categorical variables and Mann-Whitney *U* test for continuous variables.

A backward method multivariable logistic regression was performed based on those preoperative variables (demographics, health status, comorbidities) that were statistically significant (*p* \< 0.05) between cohorts in unmatched analysis. Variables in our regression methodology included, age, BMI, gender, race, American society of anesthesia (ASA) class, operation type, history of myocardial infarction, percutaneous coronary intervention, cardiac surgery, hypertension, hyperlipidemia, diabetes mellitus, smoking, renal insufficiency, dialysis, deep venous thrombosis requiring therapy, pulmonary embolism, inferior vena cava filter, and anticoagulation for presumed or confirmed venous thromboembolism (VTE) and chronic steroids.

Matching {#Sec6}
--------

Propensity and case-control matched analyses were performed to account for inter-group biases. For both propensity score and case-control matching, the ratio of transplant recipients to control patients without transplantation was 1:5. For propensity score matching, a logistic regression model was generated on variables significantly different (*p* \< 0.05) on univariate analysis between those with and without a history of solid organ transplantation. Matching variables included age, sex, race, BMI, operation type, diabetes mellitus, hypertension, hyperlipidemia, ASA class, steroid use, renal insufficiency, dialysis status, smoking status, history of pulmonary embolism, history of IVC filter preoperatively, history of VTE requiring therapy, and anticoagulation use preoperatively. A propensity score from 0 to 1 was generated from this model and assigned to each subject. A nearest-neighbor variable ratio with propensity scores that fell within a caliper of 0.05 was then used to generate matched cohorts hypothesized to be balanced on potentially confounding baseline characteristics.

For case-control matched analysis, cases and controls were matched based on clinical variables that were significantly different in univariate analysis of the unmatched cohorts. This resulted in matched cohorts with equal distributions of those variables, including age, sex, race, BMI, operation type, diabetes mellitus, hypertension, hyperlipidemia, ASA class, steroid use, renal insufficiency, dialysis status, smoking status, history of pulmonary embolism, history of IVC filter preoperatively, history of VTE requiring therapy, and anticoagulation use preoperatively.

Primary and secondary outcomes were compared with Pearson chi-square test for categorical variables and Mann- Whitney *U* test for continuous variables. Continuous data is expressed as median and interquartile range (IQR) and categorical data is expressed as frequency and percentage. Aggregate complications (Appendix 1 Table [6](#Tab6){ref-type="table"}) were also compared, including aggregate leak, bleeding, renal, cardiovascular and pulmonary complications, venous thromboembolic events, aggregate surgical site infection, and other infection. All statistical analyses were performed with SPSS version 25 (IBM Corporation, Armonk, NY) and SAS version 9.4 (SAS Institute, Cary, NC). A *p* value of \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Demographics of Study Cohorts {#Sec8}
-----------------------------

Table [1](#Tab1){ref-type="table"} shows the unmatched patient characteristics of the two cohorts. After exclusions, we identified 336 metabolic and bariatric surgery cases with a history of prior solid organ transplantation and 157,413 cases without. The transplant cohort had a higher median age (48 years vs. 44 years, *p* = 0.04) and a lower median BMI (42.5 kg/m^2^ vs. 43.9 kg/m^2^, *p* = 0.009), and was less likely to be female (69% vs. 80%, *p* \< 0.001). Surgical approaches were similar between cohorts. The transplant cohort had significantly (*p* \< 0.05) higher rates of cardiovascular disease and cardiac risks (history of MI, PCI cardiac surgery, hypertension, hyperlipidemia, and diabetes mellitus), chronic kidney disease, and prior venous thromboembolism. Smoking was more prevalent in the cohort without prior organ transplantation (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristics of unmatched cohorts(−) TXP(+) TXP*p* value\[*n* = 157,413\]\[*n* = 336\]Continuous variables, median (IQR)  Age (years)44 (35--53)48 (39--57)0.040  BMI closest to surgery (kg/m^2^)43.94 (40.15--49.28)42.53 (39.33--46.18)0.010Categorical variables, *n* (%)  Gender (female)126,002 (80)232 (69)\< 0.001  Race (White)98,528 (63)175 (52)\< 0.001  Race (Black)28,607 (18)76 (23)0.035  Ethnicity (Hispanic)19,718 (13)53 (16)0.073ASA class\< 0.001  \< 334,232 (22)34 (10)  \> 3123,181 (78)302 (90)Operation type\< 0.001  Sleeve114,290 (72)260 (77)  Gastric bypass43,123 (27)76 (23)Surgical approach0.919  Laparoscopic144,536 (92)308 (92)  Robotic12,877 (8)28 (8)Preoperative disease prevalence, *n* (%)  History of MI1870 (1)8 (2)0.044  History of PCI2814 (2)15 (4)\< 0.001  History cardiac surgery1547 (1)21 (6)\< 0.001  Hypertension74,576 (47)229 (68)\< 0.001  Hyperlipidemia35,554 (23)132 (39)\< 0.001  Diabetes mellitus39,710 (25)131 (39)\< 0.001  COPD2467 (2)3 (1)0.320  OSA60,224 (38)114 (34)0.103  Oxygen dependent1117 (1)4 (1)0.295  Smoker13,067 (8)12 (4)0.002  Renal insufficiency914 (1)47 (14)\< 0.001  Dialysis466 (0.3)30 (9)\< 0.001  VTE requiring therapy1783 (1.40)1013 (1.64)\< 0.001  History of PE1931 (1)12 (4)\< 0.001  IVC filter839 (1)5 (2)0.017  Anticoagulation4451 (3)23 (7)\< 0.001  Chronic steroids2755 (2)144 (43)\< 0.001  Limited ambulation status2312 (1)9 (3)0.066  Independent functional status155,684 (99)329 (98)0.084  History of bariatric surgery10,834 (7)26 (8)0.536*TXP* history of solid organ transplantation, *IQR* interquartile range, *kg* kilogram, *ASA* American Society of Anesthesiologist, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *COPD* chronic obstructive pulmonary disease, *OSA* obstructive sleep apnea, *PE* pulmonary emboli, *IVC* inferior vena cava, *VTE* venous thromboembolism

Outcomes Following Unmatched Cohort Analysis {#Sec9}
--------------------------------------------

Outcomes of the unmatched cohorts are detailed in Table [2](#Tab2){ref-type="table"}. There was no mortality difference (*p* = 0.17) between those who had previously undergone TXP and those who had not. Overall morbidity (12% vs. 5%, *p* \< 0.001) and bariatric-related morbidity (9% vs. 4%, *p* \< 0.001) were both significantly higher in the transplant cohort. Median operative time and post-operative length of stay were significantly longer in the transplant cohort (*p* \< 0.05). All 30-day adverse outcomes were higher in the transplant cohort, including significantly higher rates of readmission (*p* \< 0.001), intervention (*p* = 0.039), and unplanned ICU admission (*p* \< 0.001). While bleeding was similar between the two cohorts, aggregate leak (*p* = 0.0005) and VTE (*p* = 0.014), as well as aggregate cardiovascular, renal, and infectious complications, were significantly higher in the unmatched transplant cohort (Table [2](#Tab2){ref-type="table"}).Table 2Outcomes, unmatched cohorts(−) TXP(+) TXP*p* value\[*n* = 157,413\]\[*n* = 336\]Operative time, (min)\*74 (53--108)99 (67--136)\< 0.001Hospital LOS (days)\*1 (1--2)2 (1--2)\< 0.00130-day adverse outcomes and perioperative complications *n* (%)  Mortality130 (0.08)1 (0.3)0.170  Death related77 (0.05)1 (0.3)0.410  Overall morbidity7660 (5)40 (12)\< 0.001  Overall morbidity related5781 (4)29 (9)\< 0.001  Reoperation1898 (1)6 (2)0.330  Reoperation related1526 (1)6 (2)0.130  Readmission5730 (4)33 (10)\< 0.001  Readmission related4511 (3)25 (7)\< 0.001  Post-op intervention1838 (1)8 (2)0.039  Post-op intervention, related1591 (1)8 (2)0.012  ICU admission1043 (1)10 (3)\< 0.001  Follow-up149,903 (95)319 (95)0.800  Transfusion993 (1)9 (3)\< 0.001  Acute renal failure97 (0.06)2 (0.6)\< 0.001  Progressive renal failure96 (0.06)4 (1.19)\< 0.001  CPR64 (0.04)0 (0)0.710  Stroke20 (0.01)0 (0)0.840  Myocardial infarction36 (0.02)1 (0.3)\< 0.001  DVT requiring therapy280 (0.18)1 (0.3)0.600  Pulmonary embolism175 (0.11)2 (0.6)0.008  Pneumonia313 (0.2)2 (0.6)0.100  Reintubation181 (0.11)0 (0)0.530  Superficial SSI679 (0.43)4 (1.2)\< 0.001  Deep incisional SSI100 (0.06)1 (0.3)0.090  Organ space SSI354 (0.22)3 (0.89)0.030  Post-operative sepsis153 (0.1)0 (0)0.850  Post-operative septic shock95 (0.06)0 (0)0.650  Post-operative UTI564 (0.37)1 (0.3)0.970  C. diff188 (0.12)1 (0.3)0.350  Incisional hernia109 (0.07)1 (0.3)0.110  ED visit w/o admit10,835 (7)25 (7)0.690  Approach converted252 (0.16)5 (1.49)\< 0.001Aggregate complications, *n* (%)  Bleeding687 (0.44)1 (0.3)0.670  Leak747 (0.47)6 (1.79)\< 0.001  Cardiovascular160 (0.1)2 (0.6)0.005  Pulmonary724 (0.46)2 (0.6)0.710  Renal209 (0.13)6 (1.79)\< 0.001  VTE822 (0.52)5 (1.49)0.014  SSI1103 (0.7)10 (2.98)\< 0.001  Other infection1195 (0.76)4 (1.19)0.360*TXP* history of solid organ transplantation, *LOS* post-operative length of stay, *CPR* cardio-pulmonary resuscitation, *DVT* deep vein thrombosis, *SSI* surgical site infection, *C. diff* Clostridium difficile, *UTI* urinary tract infection, *VTE* venous thromboembolism\*Median (IQR), interquartile range

Outcomes Following Multivariate Logistic Regression Analysis {#Sec10}
------------------------------------------------------------

While other variables (history of VTE, chronic steroid use, myocardial infarction, male gender, age, and BMI) conferred a higher mortality risk (Appendix 2 Table [7](#Tab7){ref-type="table"}), we observe that prior solid organ transplantation did not confer a significant overall mortality (*p* = 0.55) or bariatric-related mortality (*p* = 0.99) risk (Table [3](#Tab3){ref-type="table"}). Even though prior organ transplantation did not confer a mortality difference, it was associated with significantly higher overall morbidity (OR 1.60, *p* = 0.008) and morbidity related to bariatric surgery (OR 1.78, *p* = 0.004). Prior organ transplantation also independently impacted readmission (OR 1.90, *p* \< 0.001), unplanned ICU admission (OR 2.24, *p* = 0.018), aggregate leak (OR 3.47, *p* = 0.003), and aggregate surgical site infection (OR 3.32, *p* \< 0.001) (Table [3](#Tab3){ref-type="table"}). Other variables impacting bariatric-related morbidity are shown in Appendix 2 Table [7](#Tab7){ref-type="table"}.Table 3Impact of prior transplantation on bariatric outcomes: multivariate regression analysisHistory of transplantOdds ratio95% confidence interval*p* valueOverall mortality1.860.24--14.290.550Bariatric-related mortality\< 0.0010.001--10000.990Overall morbidity1.601.13--2.280.008Bariatric-related morbidity1.781.12--2.640.004Readmission1.901.30--2.78\< 0.001Bariatric-related readmission2.201.46--3.34\< 0.001ICU admission2.241.15--4.370.018Aggregate leak3.471.54--7.870.003Aggregate bleeding0.420.06--3.010.390Aggregate VTE2.420.99--5.920.050Aggregate SSI3.321.72--6.41\< 0.001*ICU* intensive care unit, *VTE* venous thromboembolism, *SSI* surgical site infection

Outcomes Following Matching {#Sec11}
---------------------------

One-to-five propensity matching compared 285 metabolic and bariatric surgery cases with prior solid organ transplantation to 1425 cases without. Cases and controls were statistically similar (Appendix 3 Table [8](#Tab8){ref-type="table"}), except for a higher rate of chronic obstructive lung disease in the cohort without transplantation. Outcomes following propensity matched analysis are detailed in Table [4](#Tab4){ref-type="table"}*.* Similar to the unmatched cohort analysis, there was no mortality difference between these matched cohorts, but a higher rate of overall morbidity (10% vs. 6%, *p* = 0.02) and bariatric-related morbidity (7% vs. 4%, *p* = 0.05) in the transplant cohort. While leak rate was three-fold higher in the transplant cohort, the difference was not significant (*p* = 0.05) in this matched analysis.Table 4Outcomes following 1:5 propensity score matching(−) TXP(+) TXP*p* value\[*n* = 1425\]\[*n* = 285\]Operative time, (min)\*76 (54--108)100 (67--136)\< 0.001Hospital LOS (days)\*2 (1--2)2 (1--2)\< 0.00130-day outcomes, and perioperative complications *n* (%)  Mortality2 (0.14)1 (0.35)0.438  Bariatric-related mortality1 (0.7)1 (0.35)0.387  Overall morbidity87 (6)28 (10)\< 0.022  Bariatric-related morbidity57 (4)19 (7)0.046  Reoperation26 (2)6 (2)0.750  Reoperation related22 (2)6 (2)0.495  Readmission65 (5)23 (8)0.014  Readmission related42 (3)16 (6)0.023  Post-op intervention18 (1)6 (2)0.270  Post-op intervention, related14 (1)6 (2)0.108  ICU admission13 (1)7 (2)0.027  Transfusion13 (1)6 (2)0.079  Acute renal failure2 (0.07)1 (0.35)0.206  Progressive renal failure1 (0.07)1 (0.35)0.002  CPR1 (0.07)0 (0)0.655  Stroke4 (0.28)0 (0)0.371  Myocardial infarction3 (0.21)1 (0.35)0.654  DVT requiring therapy7 (0.49)3 (1.05)0.257  Pulmonary embolism2 (0.14)1 (0.35)0.438  Pneumonia4 (0.28)2 (0.7)0.273  Reintubation2 (0.14)0 (0)0.527  Superficial SSI7 (0.49)2 (0.7)0.654  Deep incisional SSI2 (0.14)1 (0.35)0.438  Organ space SSI8 (0.56)2 (0.7)0.740  Post-operative sepsis3 (0.21)0 (0)0.438  Post-operative septic shock1 (0.07)0 (0)0.655  Post-operative UTI8 (0.56)1 (0.35)0.654  C. diff4 (0.28)1 (0.35)0.841  Incisional hernia2 (0.14)1 (0.35)0.438  ED visit w/o admit108 (8)20 (7)0.742  Approach converted4 (0.28)3 (1.05)0.062Aggregate complications, *n* (%)  Bleeding7 (0.49)1 (0.35)0.751  Leak9 (0.63)5 (1.75)0.055  Cardiovascular9 (0.63)2 (0.7)0.892  Pulmonary11 (0.77)2 (0.7)0.901  Renal2 (0.14)4 (1.4)0.001  VTE11 (0.77)4 (1.4)0.297  SSI11 (0.77)7 (2.46)0.001  Other infection20 (1.4)4 (1.4)0.999*TXP* history of solid organ transplantation, *LOS* post-operative length of stay, *CPR* cardio-pulmonary resuscitation, *DVT* deep vein thrombosis, *SSI* surgical site infection, *C. diff* Clostridium difficile, *UTI* urinary tract infection, *VTE* venous thromboembolism\*Median interquartile range

Case-controlled matching compared 182 cases with 910 equally matched controls (Appendix 4 Table [9](#Tab9){ref-type="table"}). Outcomes are shown in Table [5](#Tab5){ref-type="table"}. Similar to unmatched and propensity matched analyses, operative duration (*p* \< 0.0001) and hospital length of stay (*p* = 0.03) remained significantly longer in the transplant cohort after case-control matching. There was no mortality difference. Unlike our unmatched and propensity matched analyses, there was no differences in overall and bariatric-related morbidity after case-control matching. Rates of transfusion requirement (2% vs. 0.22%, *p* = 0.009), progressive renal failure (0.55% vs. 0%, *p* = 0.025), and aggregate anastomotic or staple line leak (2.2% vs. 0.55%, *p* = 0.025) remained significantly higher in the transplant cohort, similar to unmatched and propensity matched analyses. All other outcome measures were similar in MBS patients with and without a history of a prior solid organ transplantation (Table [5](#Tab5){ref-type="table"}).Table 5Outcomes following 1:5 case-control matched analysis(−) TXP(+) TXP*p* value\[*n* = 910\]\[*n* = 182\]Operative time, (min)\*76 (53--108)104 (67--136)\< 0.001Hospital LOS (days)\*1 (1--2)2 (1--2)0.03030-day outcomes, and perioperative complications *n* (%)  Mortality0 (0)0 (0)1.000  Bariatric-related mortality0 (0)0 (0)1.000  Overall morbidity66 (7)14 (8)0.830  Bariatric-related morbidity46 (5)9 (5)0.951  Reoperation13 (1)4 (2)0.444  Reoperation related8 (1)4 (2)0.119  Readmission46 (5)12 (7)0.398  Readmission related35 (4)8 (4)0.728  Post-op intervention14 (2)4 (2)0.524  Post-op intervention, related13 (1)4 (2)0.444  ICU admission9 (1)4 (2)0.170  Follow-up870 (96)171 (94)0.336  Transfusion2 (0.22)3 (2)0.009  Acute renal failure3 (0.33)0 (0)0.438  Progressive renal failure0 (0)1 (0.55)0.025  CPR0 (0)0 (0)1.000  Stroke1 (0.11)0 (0)0.655  Myocardial infarction0 (0)0 (0)1.000  DVT requiring therapy8 (1)3 (2)0.343  Pulmonary embolism2 (0.22)1 (0.55)0.438  Pneumonia2 (0.22)0 (0)0.527  Reintubation1 (0.11)0 (0)0.655  Superficial SSI2 (0.22)1 (0.55)0.438  Deep incisional SSI2 (0.22)0 (0)0.527  Organ space SSI4 (0.44)1 (0.55)0.841  Post-operative sepsis0 (0)0 (0)1.000  Post-operative septic shock2 (0.22)0 (0)0.527  Post-operative UTI5 (0.55)0 (0)0.316  C. diff4 (0.44)0 (0)0.370  Incisional hernia0 (0)0 (0)1.000  ED visit w/o admit68 (7)14 (8)1.000  Approach converted2 (0.22)0 (0)0.527Aggregate complications, *n* (%)  Bleeding6 (1)0 (0)0.272  Leak5 (0.55)4 (2.2)0.025  Cardiovascular2 (0.22)0 (0)0.527  Pulmonary4 (0.44)0 (0)0.370  Renal3 (0.33)1 (0.55)0.654  VTE9 (1)4 (2.2)0.170  SSI6 (0.66)3 (1.65)0.178  Other infection12 (1.32)1 (0.55)0.382*TXP* history of solid organ transplantation, *LOS* post-operative length of stay, *CPR* cardio-pulmonary resuscitation, *DVT* deep vein thrombosis, *SSI* surgical site infection, *C. diff* Clostridium difficile, *UTI* urinary tract infection, *VTE* venous thromboembolism\*Median interquartile range

Discussion {#Sec12}
==========

Given the potential for poorer outcomes in obese solid organ transplantation patients, there is significant interest in identifying optimal modalities to achieve significant and durable weight loss, including metabolic and bariatric surgery. The literature regarding the safety of MBS in patients with organ transplantation continues to evolve. Current literature demonstrates that MBS is overall safe in transplant patients, but is limited to single-center experiences with small sample sizes \[[@CR1], [@CR2], [@CR12]\].

Utilizing the 2017 MBSAQIP, we show that MBS in TXP patients with prior solid organ transplantation is overall safe, with an associated low mortality. However, there is an increased rate of overall morbidity and bariatric-related morbidity compared with the general bariatric population. For both propensity and case-control matched analyses, operative duration, post-operative length of stay, and progressive renal failure remained significantly longer and higher in transplant patients. Some outcome differences were noted between our propensity and case-control matched cohorts. While a higher morbidity was noted in the transplant cohort after propensity matched analysis, it did not persist after case-control matched analysis. This was similarly noted for readmission, unplanned ICU admission, aggregate renal complications, and surgical site infection. Across analyses, leak rate remained higher in the transplant cohort. In comparison with propensity matching, case-control matching is often associated with smaller cohorts that are more tightly matched. This was the case in our analyses, and may have accounted for some of the outcome differences noted between our cohort matching techniques.

Transplantation provides a cure for end stage organ failure, but comes with lifelong immunosuppression. This may account for the increased morbidity in the TXP cohort. In our unmatched analysis, transplant patients were more likely to be on chronic steroids and have preoperative renal insufficiency. Previous matched analyses of the 2015--2016 MBSAQIP database have demonstrated that chronic kidney disease (CKD) and corticosteroid to be independent predictors of morbidity following MBS \[[@CR15], [@CR16]\]. Patients with CKD were more likely to have increased total morbidity, infectious complications, and hospital length of stay \[[@CR15]\]. Interestingly, corticosteroid use was an increased risk factor for anastomotic leak (two- to three-fold) but without an increased risk for overall morbidity \[[@CR16]\]. The increased leak rate conferred by steroids is prevalent in other surgical disciplines and throughout the literature. Although we control for both of these variables in our propensity and case-control matching techniques, these factors may still contribute to the increase leak rate and morbidity in the TXP cohort. (Reviewer \#1, Comment \#1)

Studies on post-transplantation bariatric surgery are limited, with varied outcomes \[[@CR1], [@CR12]--[@CR14], [@CR17]\]. Khoarki et al. reported their experience with 10 patients undergoing sleeve gastrectomy after liver, kidney, or heart transplant. Mortality and morbidity were 0% and 20%, respectively. In addition to significant weight loss and resolution of obesity-related conditions, they reported increased graft preservation in liver transplants, improved ejection fraction in heart transplants, and increased estimated glomerular filtration rate in renal transplants \[[@CR1]\]. In a case-control matched analysis, Cohen et al. found that post-transplantation bariatric surgery was protective for allograft failure (HR 0.85) and mortality (HR 0.80) \[[@CR14]\]. In another single-center small case series, Elli et al. compared outcomes between 10 post-transplant (kidney, liver, or pancreas) and 490 non-transplant LSG patients. Allograft function at 1 year was excellent with 100% follow-up in the transplant cohort, and there was no reported mortality or morbidity \[[@CR12]\]. Transplant specific analyses show that bariatric surgery was also safe after renal \[[@CR17]\] and liver transplantation \[[@CR13]\], with low morbidity and mortality. Our study corroborates these findings with no difference in mortality; however we found that prior solid organ transplantation increases the risk of 30-day morbidity and anastomotic leak in MBS patients.

While the published literature suggests that bariatric surgery in transplant patients has an acceptable safety profile, larger cohorts are needed to validate reported outcomes. Even though our study cannot draw conclusions about long-term outcomes (past 30 days), our study is the largest matched cohort study reporting on bariatric surgery outcomes post-transplantation. Similar to published literature, we also found that prior solid organ transplantation did not confer a significantly higher overall or bariatric-related mortality risk, compared with the general bariatric population. However, some post-operative complications remained significantly higher in the transplant cohort (transfusion requirement, renal failure, and leak) after adjusting for potential confounding variables.

Our study has several limitations. This is retrospective analysis of a clinical database that is prone to the inherent biases of such analysis. While the largest reported study on this topic, the overall transplant cohort was small and outcomes are limited to 30 days post-operatively. A sample of cases was excluded that may have impacted our outcomes. We were unable to stratify our transplant cohort by the type of solid organ transplantation performed as this variable is not available in the database. Also unavailable was information on non-solid organ transplant patients; therefore, our findings may not be generalizable to all transplant patients. Due to the small sample sizes, we were unable to stratify our analyses by bariatric procedure type (sleeve vs. gastric bypass) and surgical approach (robotic-assisted vs. conventional laparoscopic). These are potential confounders that may have impacted our findings. To limit procedure-type and surgical approach as potential confounders, these variables were equally matched in both our propensity and case-control matched analyses. Additionally, we lack the timeframe between organ transplantation and metabolic and bariatric surgery, which may impact intraoperative findings, operative course, and ultimately outcome. Finally, information regarding specific immunosuppression regimens for the transplant cohort was not available, and may have also biases biased our findings.

Conclusions {#Sec13}
===========

Despite the recognized limitations in this matched cohort study of the 2017 MBSAQIP database, we found that metabolic and bariatric surgery is overall safe in carefully selected solid organ transplantation patients compared with the general bariatric patient population, with no significant difference in overall and bariatric-related mortality. However, some complications including anastomotic leak remain higher in prior solid organ transplant patients undergoing metabolic and bariatric surgery. Further studies are needed to determine the optimal timing of metabolic and bariatric surgery in this complex patient cohort.

Appendix 1. Composite complication methodology {#Sec14}
==============================================

Table 6Methodology of aggregate complications. For each aggregate complication, composite variables are outlinedAggregate variableComposite variablesLeakReoperation with suspected reason: leakReadmission with suspected reason: leakIntervention with suspected reason: leakDrain present over 30 daysComplication: organ space SSIBleedingReoperation with suspected reason: bleedingReadmission with suspected reason: bleedingIntervention with suspected reason: bleedingCardiac/CVAReoperation with suspected reason: cardiac NOS, CVA, or MIReadmission with suspected reason: cardiac NOS, CVA, or MIIntervention with suspected reason: cardiac NOS, CVA, or MIComplication of CVAComplication of MIPulmonaryReoperation with suspected reason: shortness of breath, pneumonia, or other respiratory failureReadmission with suspected reason: shortness of breath, pneumonia, or other respiratory failureIntervention with suspected reason: shortness of breath, pneumonia, or Other respiratory failureComplication: on ventilator \> 48 hComplication: unplanned intubationComplication: pneumoniaRenalReoperation with suspected reason: renal insufficiencyReadmission with suspected reason: renal insufficiencyIntervention with suspected reason: renal insufficiencyComplication: progressive renal insufficiencyComplication: acute renal failureDVT or PEReoperation with suspected reason: vein thrombosis requiring therapy or pulmonary embolismReadmission with suspected reason: vein thrombosis requiring therapy or pulmonary embolismIntervention with suspected reason: vein thrombosis requiring therapy or pulmonary embolismComplication: vein thrombosis requiring therapyComplication: pulmonary embolismComplication: anticoagulation initiated of presumed/confirmed vein thrombosis/PEWound infectionReoperation with suspected reason: wound infection or other abdominal sepsisReadmission with suspected reason: wound infection or other abdominal sepsisIntervention with suspected reason: wound infection or other abdominal sepsisComplication: Post-op superficial incisional SSI occurrenceComplication: Post-op deep incisional SSI occurrenceOther infectionReoperation with suspected reason: infection/feverReadmission with suspected reason: infection/fever,Intervention with suspected reason: infection/feverComplication: post-op sepsis occurrenceComplication: post-op septic shock occurrenceComplication: post-op pneumonia occurrenceComplication: post-op urinary tract infection occurrenceOverall morbidityMortality within 30 daysNeed for intervention within 30 daysNeed for readmission within 30 daysNeed for reoperation within 30 daysUnplanned ICU transfer within 30 daysAggregate-related reoperationAny reoperation designated as related to metabolic/bariatric by variable REOP_RELATED_BAR1. To REOP_RELATED_BAR.13Aggregate-related readmissionAny readmission designated as related to metabolic/bariatric by variable READ_RELATED_BAR1. To READ_RELATED_BAR.11Aggregate-related interventionAny intervention designated as related to metabolic/bariatric by variable INVT_RELATED_BAR1. To INTV_RELATED_BAR.5Bariatric surgery--related morbidityDeath related to bariatric surgeryAggregate reoperation related to metabolic/bariatric surgeryAggregate readmission related to metabolic/bariatric surgeryAggregate intervention related to metabolic/bariatric surgery

Appendix 2. Independent predictors of mortality and morbidity following sleeve and gastric bypass {#Sec15}
=================================================================================================

Table 7Independent predictors of mortality and morbidity following sleeve and gastric bypass following multivariate regression analysisOverall mortalityOdds ratio95% confidence interval*p* valueVTE2.531.30--4.950.006Chronic steroids2.391.09--5.260.030Myocardial infarction2.341.15--4.780.020Male sex2.241.47--2.99\< 0.001Anticoagulation for VTE2.121.22--3.680.007Age1.051.04--1.07\< 0.001BMI1.051.04--1.07\< 0.001Bariatric-related mortalityOdds ratio95% confidence interval*p* valueBMI1.041.00--1.090.03Overall morbidityOdds ratio95% confidence interval*p* valueHistory of IVC filter1.741.41--2.15\< 0.001History of dialysis1.701.28--2.28\< 0.001History of chronic steroids1.551.35--1.78\< 0.001History of DVT1.531.32--1.77\< 0.001History of anticoagulation1.461.30--1.64\< 0.001History of PE1.421.20--1.67\< 0.001History of MI1.421.20--1.67\< 0.001History of cardiac disease1.321.10--1.580.003History of renal insufficiency1.261.00--1.590.045ASA \> 31.151.07--1.22\< 0.001History of smoking1.131.04--1.220.004History of hyperlipidemia1.121.06--1.200.002History of hypertension1.101.04--1.160.001BMI1.011.00--1.01\< 0.00Age1.001.00--1.010.031Laparoscopic (vs. robotic)0.900.84--0.980.017Male sex0.880.83--0.94\< 0.001White (vs. Black)0.770.73--0.82\< 0.001Bariatric-related morbidityOdds ratio95% confidence interval*p* valueHistory of TXP1.781.12--2.640.004History of DVT1.691.42--2.00\< 0.001History of IVC filter1.551.21--2.00\< 0.001History of dialysis1.541.10--2.150.012History of PE1.531.27--1.95\< 0.001History of MI1.481.22--1.79\< 0.001History of diabetes1.451.31--1.60\< 0.001History of chronic steroids1.361.15--1.600.003History of anticoagulation1.231.06--1.410.049ASA \> 31.171.09--1.25\< 0.001History of hyperlipidemia1.161.09--1.24\< 0.001History of smoking1.141.04--1.240.006BMI1.001.00--1.010.002Laparoscopic (vs. robotic)0.900.82--0.990.267Male sex0.820.77--0.88\< 0.001*VTE* venous thromboembolism, *BMI* body mass index, *IVC* inferior vena cava, *DVT* deep vein thrombosis, *PE* pulmonary emboli, *MI* myocardial infarction, *ASA* American Society of Anesthesiologist, *TXP* history of solid organ transplantation

Appendix 3. Patient characteristics after 1:5 propensity score matching {#Sec16}
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Table 8Patient characteristics after propensity score matching(−) TXP(+) TXP*p* value\[*n* = 1425\]\[*n* = 285\]Continuous variables, median (IQR)  Age (years)48 (38--57)48 (39--56)0.832  BMI closest to surgery (kg/m^2^)43.07 (39.4--48.55)42.57 (39.53--46.59)0.204Categorical variables, *n* (%)  Gender (female)1048 (74)207 (73)0.750  Race (White)748 (52)154 (54)0.634  Race (Black)305 (21)62 (22)0.895  Ethnicity (Hispanic)247 (17)45 (16)0.527ASA class0.945  \< 3158 (11)32 (11)  \> 31267 (89)253 (89)Operation type0.438  Sleeve1028 (72)212 (74)  Gastric bypass397 (28)73 (26)  Surgical approach0.661Laparoscopic1309 (92)264 (93)Robotic116 (8)21 (7)Preoperative disease prevalence, *n* (%)  History of MI28 (2)6 (2)0.877  History of PCI65 (5)12 (4)0.794  History cardiac surgery56 (4)11 (4)0.956  Hypertension922 (65)185 (65)0.946  Hyperlipidemia537 (38)102 (36)0.546  Diabetes mellitus551 (39)102 (36)0.591  COPD58 (4)3 (1)*0.012*  OSA455 (32)90 (32)0.908  Oxygen dependent34 (2)2 (1)0.071  Smoker70 (5)11 (4)0.445  Renal insufficiency108 (8)20 (7)0.742  Dialysis71 (5)15 (5)0.843  VTE requiring therapy42 (3)9 (3)0.849  History of PE43 (3)9 (3)0.900  IVC filter20 (1)3 (1)0.639  Anticoagulation77 (5)18 (6)0.539  Chronic steroids455 (32)93 (33)0.817  Limited ambulation status46 (3)6 (2)0.316  Independent functional status1393 (98)282 (99)0.194  History of bariatric surgery106 (7)20 (7)0.804*TXP* history of solid organ transplantation, *IQR* interquartile range, *BMI* body mass index, *kg* kilogram, ASA American Society of Anesthesiologist, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *COPD* chronic obstructive pulmonary disease, *OSA* obstructive sleep apnea, *PE* pulmonary emboli, *IVC* inferior vena cava, *VTE* venous thromboembolism

Appendix 4. Patient characteristics after 1:5 case-control matched analysis {#Sec17}
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Table 9Patient characteristics after case-control matching(−) TXP(+) TXP*p* value\[*n* = 910\]\[*n* = 182\]Continuous variables, median (IQR)  Age (years)45 (36--75)46 (38--72)0.45  BMI closest to surgery (kg/m^2^)43.6 (39.6--49)42.6 (39.6--47)0.42  Categorical variables, *n* (%)  Gender (female)740 (81)148 (81)1  Race (White)515 (57)103 (57)1  Race (Black)170 (19)34 (19)1  Ethnicity (Hispanic)144 (16)29 (16)0.97ASA class1  \< 3125 (14)25 (14)  \> 3785 (86)157 (86)Operation type1  Sleeve640 (70)128 (70)  Gastric bypass270 (30)54 (30)Surgical approach1  Laparoscopic833 (92)168 (92)  Robotic77 (8)14 (8)Preoperative disease prevalence  History of MI5 (0.55)1 (0.55)1  History of PCI0 (0)0 (0)1  History cardiac surgery5 (0.55)1 (0.55)1  Hypertension490 (54)98 (54)1  Hyperlipidemia245 (27)49 (27)1  Diabetes mellitus250 (27)50 (27)1  COPD25 (3)3 (2)0.39  OSA240 (26)48 (26)1  Oxygen dependent8 (1)1 (1)1  Smoker35 (4)7 (4)1  Renal insufficiency0 (0)0 (0)1  Dialysis0 (0)0 (0)1  VTE requiring therapy0 (0)0 (0)1  History of PE5 (0.55)1 (0.55)1  IVC filter5 (0.55)1 (0.55)1  Anticoagulation5 (0.55)1 (0.55)1  Chronic steroids155 (17)31 (17)1  Limited ambulation status6 (1)3 (2)0.18  Independent functional status898 (99)182 (100)0.12  History of bariatric surgery63 (7)10 (5)0.48*TXP* history of solid organ transplantation, *IQR* interquartile range, *kg* kilogram, *ASA* American Society of Anesthesiologist, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *COPD* chronic obstructive pulmonary disease, *OSA* obstructive sleep apnea, *PE* pulmonary emboli, *IVC* inferior vena cava, *VTE* venous thromboembolism
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